{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:52:59Z","timestamp":1791262379985,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005230","name":"Natural Science Foundation of Chongqing Municipality","doi-asserted-by":"publisher","award":["CSTB2023NSCQ-MSX0234"],"award-info":[{"award-number":["CSTB2023NSCQ-MSX0234"]}],"id":[{"id":"10.13039\/501100005230","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005230","name":"Natural Science Foundation of Chongqing Municipality","doi-asserted-by":"publisher","award":["CSTB2024NSCQ-MSX0157"],"award-info":[{"award-number":["CSTB2024NSCQ-MSX0157"]}],"id":[{"id":"10.13039\/501100005230","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bioorg.2026.110495","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T16:16:35Z","timestamp":1788970595000},"page":"110495","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Design, synthesis, and biological evaluation of the first fibroblast growth factor receptor 4 PROTAC degrader"],"prefix":"10.1016","volume":"182","author":[{"given":"Yuehui","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomeng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuzhu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juntong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qihua","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongjie","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.110495_bb0005","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/jb\/mvq121","article-title":"Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease","volume":"149","author":"Itoh","year":"2010","journal-title":"J. Biochem."},{"key":"10.1016\/j.bioorg.2026.110495_bb0010","doi-asserted-by":"crossref","first-page":"57633","DOI":"10.18632\/oncotarget.9328","article-title":"Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival","volume":"7","author":"Tiong","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioorg.2026.110495_bb0015","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41523-019-0114-x","article-title":"FGFR4 overexpression and hotspot mutations in metastatic ER+ breast cancer are enriched in the lobular subtype","volume":"5","author":"Levine","year":"2019","journal-title":"npJ Breast Cancer"},{"key":"10.1016\/j.bioorg.2026.110495_bb0020","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1007\/s10620-013-2609-x","article-title":"Expression of fibroblast growth factor 19 is associated with recurrence and poor prognosis of hepatocellular carcinoma","volume":"58","author":"Hyeon","year":"2013","journal-title":"Digest Dis Sci"},{"key":"10.1016\/j.bioorg.2026.110495_bb0025","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1159\/000335472","article-title":"Targeting fibroblast growth factor receptor signaling in hepatocellular carcinoma","volume":"81","author":"Cheng","year":"2011","journal-title":"Oncology"},{"key":"10.1016\/j.bioorg.2026.110495_bb0030","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.lungcan.2019.02.007","article-title":"FGFR4 increases EGFR oncogenic signaling in lung adenocarcinoma, and their combined inhibition is highly effective","volume":"131","author":"Quintanal-Villalonga","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.bioorg.2026.110495_bb0035","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.2147\/OTT.S81659","article-title":"The prognostic significance of fibroblast growth factor receptor 4 in non-small-cell lung cancer","volume":"8","author":"Huang","year":"2015","journal-title":"Onco. Targets Ther."},{"key":"10.1016\/j.bioorg.2026.110495_bb0040","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.7150\/thno.82269","article-title":"FGF19-mediated ELF4 overexpression promotes colorectal cancer metastasis through transactivating FGFR4 and SRC","volume":"13","author":"Chen","year":"2023","journal-title":"Theranostics"},{"key":"10.1016\/j.bioorg.2026.110495_bb0045","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/sj.onc.1210623","article-title":"Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models","volume":"27","author":"Desnoyers","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.bioorg.2026.110495_bb0050","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1159\/000489759","article-title":"FGFR4 links glucose metabolism and chemotherapy resistance in breast cancer","volume":"47","author":"Xu","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.bioorg.2026.110495_bb0055","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1158\/2159-8290.CD-14-1029","article-title":"First selective small molecule inhibitor of FGFR4 for the treatment of hepatocellular carcinomas with an activated FGFR4 signaling pathway","volume":"5","author":"Hagel","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioorg.2026.110495_bb0060","doi-asserted-by":"crossref","first-page":"6999","DOI":"10.1158\/0008-5472.CAN-17-1865","article-title":"H3B-6527 is a potent and selective inhibitor of FGFR4 in FGF19-driven hepatocellular carcinoma","volume":"77","author":"Joshi","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110495_bb0065","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1158\/2159-8290.CD-19-0555","article-title":"First-in-human phase I study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma","volume":"9","author":"Kim","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioorg.2026.110495_bb0070","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1038\/s12276-020-00524-4","article-title":"FGF401 and vinorelbine synergistically mediate antitumor activity and vascular normalization in FGF19-dependent hepatocellular carcinoma","volume":"52","author":"Huynh","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.bioorg.2026.110495_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105673","article-title":"Design, synthesis, and biological evaluation of quinazoline derivatives with covalent reversible warheads as potential FGFR4 inhibitors","volume":"121","author":"Nie","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110495_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117206","article-title":"Design, synthesis, and biological evaluation of Ponatinib-based-Phenylpyrimidine-2-amine derivatives as novel fibroblast growth factor receptor 4 (FGFR4) selective inhibitors","volume":"284","author":"Han","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110495_bb0085","doi-asserted-by":"crossref","first-page":"11484","DOI":"10.1021\/acs.jmedchem.0c00044","article-title":"Development of a potent and specific FGFR4 inhibitor for the treatment of hepatocellular carcinoma","volume":"63","author":"Rezende Miranda","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110495_bb0090","doi-asserted-by":"crossref","first-page":"7278","DOI":"10.1021\/acs.jmedchem.2c00255","article-title":"Discovery of novel 7-Azaindole derivatives as selective covalent fibroblast growth factor receptor 4 inhibitors for the treatment of hepatocellular carcinoma","volume":"65","author":"Zhong","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110495_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115628","article-title":"Design, synthesis and biological evaluation of indazole derivatives as selective covalent inhibitors of FGFR4 in wild-type and gatekeeper mutants","volume":"258","author":"Yang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110495_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118303","article-title":"Development of a series of novel potent and selective irreversible covalent FGFR4 inhibitors with a mix-and-match strategy","volume":"302","author":"Huang","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110495_bb0105","doi-asserted-by":"crossref","first-page":"E4869","DOI":"10.1073\/pnas.1403438111","article-title":"Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors","volume":"111","author":"Tan","year":"2014","journal-title":"P. Natl. Acad. Sci. USA."},{"key":"10.1016\/j.bioorg.2026.110495_bb0110","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1158\/2159-8290.CD-19-0367","article-title":"Acquired on-target clinical resistance validates FGFR4 as a driver of hepatocellular carcinoma","volume":"9","author":"Hatlen","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioorg.2026.110495_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115947","article-title":"Insight into the design of fgfr4 selective inhibitors in cancer therapy: prospects and challenges","volume":"263","author":"Chen","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110495_bb0120","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cell.2019.11.031","article-title":"Proteolysis-targeting chimeras as therapeutics and tools for biological discovery","volume":"181","author":"Burslem","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2026.110495_bb0125","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.cbpa.2019.02.022","article-title":"Targeted protein degradation: elements of PROTAC design","volume":"50","author":"Paiva","year":"2019","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.bioorg.2026.110495_bb0130","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"P. Natl. Acad. Sci. USA."},{"key":"10.1016\/j.bioorg.2026.110495_bb0135","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2021.707317","article-title":"E3 ligase ligands in successful PROTACs: an overview of syntheses and linker attachment points","volume":"9","author":"BricelJ","year":"2021","journal-title":"Front. Chem."},{"key":"10.1016\/j.bioorg.2026.110495_bb0140","doi-asserted-by":"crossref","first-page":"7066","DOI":"10.1039\/D2CS00220E","article-title":"Chemistries of bifunctional PROTAC degraders","volume":"51","author":"Cao","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.bioorg.2026.110495_bb0145","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nchembio.1858","article-title":"Catalytic in vivo protein knockdown by small-molecule PROTACs","volume":"11","author":"Bondeson","year":"2015","journal-title":"Nat. Chem. Bio."},{"key":"10.1016\/j.bioorg.2026.110495_bb0150","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.chembiol.2017.09.010","article-title":"Lessons in PROTAC design from selective degradation with a promiscuous warhead","volume":"25","author":"Bondeson","year":"2018","journal-title":"Cell Chem. Bio."},{"key":"10.1016\/j.bioorg.2026.110495_bb0155","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1021\/ja039025z","article-title":"Chemical genetic control of protein levels: selective in vivo targeted degradation","volume":"126","author":"Schneekloth","year":"2004","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bioorg.2026.110495_bb0160","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.chembiol.2017.09.009","article-title":"The advantages of targeted protein degradation over inhibition: an RTK case study","volume":"25","author":"Burslem","year":"2018","journal-title":"Cell Chem. Bio."},{"key":"10.1016\/j.bioorg.2026.110495_bb0165","doi-asserted-by":"crossref","first-page":"17019","DOI":"10.1021\/jacs.8b08008","article-title":"Addressing kinase-independent functions of Fak via PROTAC-mediated degradation","volume":"140","author":"Cromm","year":"2018","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bioorg.2026.110495_bb0170","article-title":"Targeted protein degradation in cancers: orthodox PROTACs and beyond","volume":"4","author":"Li","year":"2023","journal-title":"Int. J. Hydrogen Energy"},{"key":"10.1016\/j.bioorg.2026.110495_bb0175","doi-asserted-by":"crossref","first-page":"15905","DOI":"10.1002\/anie.202101328","article-title":"Discovery of a potent degrader for fibroblast growth factor receptor 1\/2","volume":"60","author":"Du","year":"2021","journal-title":"Angew. Chem. Int. Edit."},{"key":"10.1016\/j.bioorg.2026.110495_bb0180","doi-asserted-by":"crossref","first-page":"7438","DOI":"10.1021\/acs.jmedchem.3c00150","article-title":"Discovery of a selective and orally bioavailable FGFR2 degrader for treating gastric cancer","volume":"66","author":"Ma","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110495_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116780","article-title":"Synthesis and identification of a selective FGFR2 degrader with potent antiproliferative effects in gastric cancer","volume":"277","author":"Feng","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110495_bb0190","doi-asserted-by":"crossref","first-page":"13858","DOI":"10.1021\/acs.jmedchem.5c00731","article-title":"Lc-mf-4, a novel fgfr3 degrader for therapeutic intervention in fgfr3-altered cancers","volume":"68","author":"Zheng","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110495_bb0195","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nchembio.925","article-title":"Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles","volume":"8","author":"Serafimova","year":"2012","journal-title":"Nat. Chem. Bio."},{"key":"10.1016\/j.bioorg.2026.110495_bb0200","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/s41589-018-0204-3","article-title":"Selective and reversible modification of kinase cysteines with chlorofluoroacetamides","volume":"15","author":"Shindo","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bioorg.2026.110495_bb0205","doi-asserted-by":"crossref","first-page":"4268","DOI":"10.1038\/s41467-020-17997-6","article-title":"Enhancing intracellular accumulation and target engagement of PROTACs with reversible covalent chemistry","volume":"11","author":"Guo","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2026.110495_bb0210","doi-asserted-by":"crossref","first-page":"7510","DOI":"10.1021\/acs.jmedchem.0c00471","article-title":"Discovery of SHP2-D26 as a first, potent, and effective PROTAC degrader of SHP2 protein","volume":"63","author":"Wang","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110495_bb0215","doi-asserted-by":"crossref","first-page":"8445","DOI":"10.1021\/acs.jmedchem.4c00758","article-title":"Discovery of 2,6-naphthyridine analogues as selective FGFR4 inhibitors for hepatocellular carcinoma","volume":"67","author":"Oh","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110495_bb0220","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1080\/00498254.2019.1643941","article-title":"Correlation of the in vitro biotransformation of H3B-6527 in dog and human hepatocytes with the in vivo metabolic profile of 14C-H3B-6527 in a dog mass balance study","volume":"50","author":"Colombo","year":"2020","journal-title":"Xenobiotica"},{"key":"10.1016\/j.bioorg.2026.110495_bb0225","doi-asserted-by":"crossref","first-page":"16231","DOI":"10.1039\/C9RA10871H","article-title":"Identification and characterization of in silico, in vivo, in vitro, and reactive metabolites of infigratinib using LC-ITMS: bioactivation pathway elucidation and in silico toxicity studies of its metabolites","volume":"10","author":"Al-Shakliah","year":"2020","journal-title":"RSC Adv."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682601031X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682601031X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:20:36Z","timestamp":1791260436000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004520682601031X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":45,"alternative-id":["S004520682601031X"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110495","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and biological evaluation of the first fibroblast growth factor receptor 4 PROTAC degrader","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110495","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110495"}}